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Crosstalklear bodies (PML NBs) are dynamic macromolecular multiprotein complexes that
recruit and release a plethora of proteins. A considerable number of PML NB components play vital roles in
apoptosis, senescence regulation and tumour suppression. The molecular basis by which PML NBs control
these cellular responses is still just beginning to be understood. In addition to PML itself, numerous further
tumour suppressors including transcriptional regulator p53, acetyl transferase CBP (CREB binding protein)
and protein kinase HIPK2 (homeodomain interacting protein kinase 2) are recruited to PML NBs in response
to genotoxic stress or oncogenic transformation and drive the senescence and apoptosis response by
regulating p53 activity. Moreover, in response to death-receptor activation, PML NBs may act as nuclear
depots that release apoptotic factors, such as the FLASH (FLICE-associated huge) protein, to amplify the death
signal. PML NBs are also associated with other nuclear domains including Cajal bodies and nucleoli and share
apoptotic regulators with these domains, implying crosstalk between NBs in apoptosis regulation. In
conclusion, PML NBs appear to regulate cell death decisions through different, pathway-speciﬁc molecular
mechanisms.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Apoptosis is a vital process both in normal development and in the
prevention of malignant cell growth. Apoptosis can occur via two
principal routes, the intrinsic and the extrinsic pathway [1,2]. The
extrinsic pathway is triggered by the binding of death ligands of the
TNF (tumour necrosis factor) superfamily, for instance Fas ligand,
TNFα or TRAIL (TNF-related apoptosis-inducing ligand), to their
receptors on the cell surface, such as CD95/Fas or the TNF receptor.
This results in the recruitment of the death inducing signalling
complex (DISC) at their intracellular domains. The DISC promotes the
cleavage and thereby activation of initiator caspases, most promi-
nently caspase-8, leading to activation of effector caspases, such as
caspases 3 and 9, and eventually to cell death. The extrinsic pathway is
thought to be the body's own way of controlling malignant cell
growth, as for instance TRAIL was shown to predominantly kill
primary cancer cells or cancer cell lines as compared to normal tissue
[3]. The intrinsic apoptosis pathway requires pro-apoptotic molecules
of the Bcl-2 (B-cell lymphoma-2) family, which act primarily at
mitochondria [4]. The activation of these proteins leads to the loss of
the mitochondrial membrane potential, cytochrome C release and to
the formation of the apoptosome. This apoptosome, which among
other regulators contains Apaf-1 (apoptotic protease-activating factor
1) and caspase-9, can in turn activate a caspase cascade and trigger
apoptosis [5]. This pathway is predominantly activated in response tol rights reserved.irradiation or other cytotoxic stress and is therefore exploited in
cancer therapy by ionizing radiation (IR) or chemotherapeutic drugs
such as doxorubicin or etoposide. However, these chemotherapeutic
drugs can also upregulate death receptors and their ligands and thus
mediate apoptosis induction via the extrinsic pathway (recently
reviewed in [6]). Extrinsic and intrinsic pathways converge in some
cell species, so-called type II cells, in which activation of the DISC does
not directly activate effector caspase-3 in the cytoplasm, but upon
caspase-8 activation at the plasma membrane engages the mitochon-
drial pathway in an as yet not fully clariﬁed mechanism, leading to
apoptosome formation and cell death [2]. A master regulator of both
intrinsic and extrinsic apoptotic pathways is the p53 protein, which
acts as a sensor of DNA damage and cytotoxic stress and enhances the
transcription of genes coding for many pro-apoptotic proteins such as
the CD95 ligand, but also several caspases and Bcl-2 family members,
sensitizing cells to various kinds of apoptotic stimuli (recently
reviewed in [7,8]).
The nucleus of mammalian cells is a remarkably complex
organelle, suborganized in multiple nuclear domains, including the
heterogeneous family of macromolecular nuclear bodies (NBs),
including Cajal bodies and PML NBs [9]. In this review we discuss
the current knowledge about the role of PML NBs in apoptosis
regulation, and disclose potential crosstalk with other types of NBs.
2. The PML nuclear body (PML NB)
Within the last decade, the doughnut-shaped subnuclear domains
characterized by the promyelocytic leukemia protein (PML) have
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infection and prevention of transformation, DNA repair, regulation of
transcription and, importantly, the induction of apoptosis and cellular
senescence [10,11]. Intriguingly, it was shown that PML knockout mice
are viable, but very susceptible to chemically induced carcinogenesis
[12], and that overexpressed PML inhibits tumour formation in nude
mice [13], suggesting that the PML protein may act as a tumour
suppressor. This is at least in part due to the central role of PML in
apoptosis induction, as PML knockout cells are largely protected
against both p53-dependent and -independent apoptosis induction,
e.g. induced by IR, interferons, ceramide, TNFα and CD95 activation,
and also to oncogene-induced senescence [12,14].
PML NBs exist in almost all mammalian cells and their diameter
ranges from about 200nm to 1µm in size. PML NBs are dynamic
structures that move within the cell nucleus in intimate contact with
the surrounding chromatin [15]. In addition to PML itself, they contain
the Sp100 protein as a second constitutive component, and these two
proteins appear to be highly modiﬁed with SUMO (small ubiquitin-
related modiﬁer) [16]. PML, the organizer of PML NBs, contains three
covalent SUMO modiﬁcation sites and one SUMO interaction motif
(SIM), which non-covalently binds SUMO [17]. Most PML NB
components are also sumoylated or bind to SUMO [16], indicating a
fundamental role of SUMO in PML NB formation and recruitment of
other proteins to PML NBs. Recent data obtained in yeast even suggest
that PML may act as a SUMO E3 ligase [18]. It will be interesting to see
whether this ﬁnding can be transferred to mammalian cells.
The PML protein contains an N-terminal RING ﬁnger, which is
characteristic for E3 ligases, two B-boxes and a leucine-rich coiled-coil
domain, which are encoded by the ﬁrst 3 exons of the PML gene, and
thus belongs to the RBCC family. However, 7 groups of isoforms (PML-I
to VII) have been described which differ in their C-termini, due to
alternative splicing of exons 4 to 9 [19,20] (Fig. 1). When single
isoforms are exogenously expressed in PML−/− cells, they form distinct
structures in the nucleus that clearly differ from each other [21]. The
different PML isoforms may therefore bind their own subset of
interaction partners and thereby fulﬁl, in part, non-redundant
functions in the cell, although isolated expression of single PML
isoforms does not reﬂect the physiological situation in the cell whereFig. 1. PML isoforms. The ﬁrst three exons, marked in blue, are present in every isoform. The
isoforms have been described which are alternatively spliced in the region between exonsmultiple isoforms appear to be expressed in combination and
contribute to PML NB structure. Although themost abundant isoforms
are PML-I and PML-II [21], the best investigated isoform is probably
PML-IV, which regulates the recruitment and activation of p53 in PML
NBs [22], facilitating apoptosis or cellular senescence upon cytotoxic
stress. Moreover, PML-IV and also PML-III were shown to exhibit
antiviral activity [23]. Recent kinetic analyses with several GFP-tagged
PML isoforms point to PML-V as potential scaffold of the PML NBs,
since it shows the longest residence time [143]. Further analysis,
namely speciﬁc depletion of the endogenous PML proteins, will clearly
help to clarify which of the known PML functions is mediated by
which PML isoform(s).
Besides the “conventional” PML NB, a number of PML-containing
nuclear structures have been described lately. For instance, in mitosis,
PML-containing structures are formed that differ strongly from
interphase bodies, since they do not contain Sp100, and were
therefore termed mitotic accumulations of PML protein (MAPPs)
[24,25]. A further type of PML-containing nuclear substructures is the
ALT (alternative lengthening of telomeres)-associated NBs [26], which
were found in telomerase-negative cancer cell lines that utilize a
homologous recombination mechanism to maintain their telomere
length and to circumvent replicative senescence [27]. In ALT cells,
PML-containing bodies were found to colocalize with telomeric DNA,
and ALT NBs may play a role in homologous recombination as well as
acting as sensors for critically short telomeres. The ALT NBs have been
shown to contain DNA repair proteins [28,29], checkpoint kinase ATM
(ataxia-telangiectasia mutated) and p53, and both proteins can be
activated in response to telomere shortening; however, the affected
cells mostly respond with cell cycle arrest and cellular senescence
rather than apoptosis.
PML NBs have been shown to contain a variety of enzymes and
transcription factors. The nuclear protein database lists close to 80
proteins that localize toNBs (http://npd.hgu.mrc.ac.uk/compartments/
pml.html), includingDNAdamage responsive proteins such as theDNA
double-strand break (DSB) Mre11/Rad50/NBS1 (MRN) sensor complex
[30–32], Bloom's syndrome helicase [33] and critical apoptosis
regulators such as the transcriptional repressor Daxx [33,34], tumour
suppressor p53 [14,22,35,36], CBP [14,22,37,38], HIPK2 [38,39], theseven subgroups are deﬁned via alternative splicing of exons 7 to 9, but more recently,
4 and 6, sometimes resulting in cytoplasmic PML proteins.
Table 1
PML NB components associated with the DNA damage response and apoptosis
regulation
Protein Function Associated disease Refs.
ATM S/T kinase, checkpoint signalling Ataxia-telangiectasia [29]
ATR S/T kinase, checkpoint signalling Seckel syndrome [139]
BLM RecQ family helicase Bloom's syndrome [33]
CBP Acetyl transferase Rubinstein–Taybi
syndrome
[37]
Chk2 S/T kinase, checkpoint signalling [97]
CK1 Ser/Thr kinase [50]
CK2 Ser/Thr kinase [140]
Daxx Transcriptional corepressor, scaffold [33,34]
Dlk/ZIPK S/T kinase [141]
FLASH Scaffold; apoptosis/cell
cycle regulation
[41]
HAUSP Ubiquitin protease [75–77]
HIPK2 S/T kinase [38,39]
MDM2 E3 ubiquitin ligase [42]
MRE11 MRN complex, DNA
damage response
Ataxia-telangiectasia-
like
[30]
NBS1 MRN complex, DNA
damage response
Nijmegen breakage
syndrome
[30]
p300 Acetyl transferase, E3
ubiquitin ligase?
[142]
p53 Transcription factor, apoptosis/cell
cycle regulation
Li–Fraumeni
syndrome
[14,22,35,36]
Par-4 aPKC inhibition [93,95]
Piasy SUMO E3 ligase [103]
PML Scaffold, transcriptional regulator APL [33]
pRb Transcription factor, scaffold Retinoblastoma [40]
RNF4/
SNURF
Sumo-dependent E3
ubiquitin ligase
[137,138]
SirT1 Class III histone deacetylase [71]
Sp100 Scaffold? [16]
THAP1 DNA binding protein,
transcription factor
[95]
TIP60 Acetyl transferase [68]
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the ubiquitin/SUMOproteinmodiﬁcation systems, for instance the p53
ubiquitin ligase MDM2/HDM2 (mouse/human double minute 2) [42]
and the ubiquitin ligase RNF4 (ring ﬁnger protein 4), which seems to
degrade PML (see below). A list of the PML NB components linked to
apoptosis regulation is shown in Table 1. Interestingly, most PML NB
proteins are transient residents and are recruited or released upon
different cellular stress signals. Most prominently, tumour suppressor
p53 has been shown to associate with PML NBs after DNA damage
induced by IR, UV or treatment with agents such as cisplatin or
adriamycin. At the PML NB, p53 can be phosphorylated at serine
residue 46 after lethal DNA damage (see below), and it can be
acetylated by acetyl transferases such as Tip60 (Tat-interactive protein
60), CBP or p300, which enhances the activity of p53 towards its pro-
apoptotic target genes. This will be discussed below in more detail.
3. PML NBs and p53 regulation
The p53 gene is mutated in more than 50% of human cancer, and in
the presence of an intact gene, the tumour suppressor p53 is often
inactivated by other mechanisms, such as upregulation of its E3
ubiquitin ligases MDM2/HDM2, Pirh2 and COP1 [43]. In unstressed,
healthy cells, p53 levels are kept low via proteasomal degradation [43].
In response tomany kinds of stress, includingUV and IR, hypoxia, DNA-
damaging chemotherapeutic drugs or redox stress, p53 is stabilized
and activated and can induce the transcription of its target genes,
leading to cell cycle arrest, senescence or apoptosis [44]. Interestingly,
PML itself was recently found to be a p53 target gene [45], suggesting a
positive feedback loop for p53-dependent cell fate regulation. Upon
DNA damage p53 is recruited into PML NBs where its apoptosis- and
senescence-driving activity is regulated by its interactionwith PML-IV
and CBP, which control p53 Lys382 acetylation [14,22,35,36]. Depend-ing on the strength of genotoxic stress, p53 is differentially modiﬁed
and activates distinct sets of target genes. For instance, the p21 gene is
already activated after mild cell damage [46], and its expression blocks
cell cycle progression to allow repair of the damage. Sublethal damage
already leads to phosphorylation of p53 at serine residues 15 and 20
and at threonine 18, resulting in the dissociation of PML from MDM2/
HDM2 (reviewed in [47]). Ser20 phosphorylation can be mediated by
checkpoint kinase Chk2, which localizes to PMLNBs and exits PMLNBs
upon DNA damage [48]. Casein Kinase 1 (CK1) can phosphorylate p53
on Ser9 and Thr18 [49], and this phosphorylation is enhanced by PML-
IV [50]. In addition, CK1 directly phosphorylates MDM2 in the acidic
loop, again weakening p53-MDM2-interaction (reviewed in [51]). The
induction of pro-apoptotic p53 target genes, such as Puma, p53AIP and
Bax, is strongly correlated with phosphorylation of Ser46 of p53 [52],
which enhances p53 acetylation at Lysine 382 by CBP/p300 [38]. In
parallel, Ser46 phosphorylation leads to isomerisation of p53 by the
peptidyl prolyl-isomerase Pin1, resulting in the dissociation of p53
from its inhibitor iASPP (inhibitory apoptosis stimulating protein of
p53) [53], and also from the ubiquitin ligase MDM2 [54]. Pin1 was also
shown to increase the acetylation of p53, but some evidence suggests
that although Pin1 was shown to partially reside in PML NBs [55,56], it
may also act on promoter-associated p53 [53]. Conversely, phosphor-
ylation-dependent degradation of unsumoylated PML was recently
shown to be facilitated by Pin1 [55], which signiﬁcantly inhibited
apoptosis induction by hydrogen peroxide in a breast cancer cell line.
This indicates that Pin1 exerts different functions in stressed and
unstressed cells, underscoring its multifunctionality (reviewed in
[57]).
Several kinases have been described to phosphorylate Ser46 on p53
in response to DNA damage: p38 [58], DYRK2 (dual-speciﬁcity tyrosine-
phosphorylation regulated kinase 2) [59], Cdk5 (cyclin-dependent
kinase 5) [60] and HIPK2 [38,39]. Of these, the function of HIPK2 has
beenmost thoroughly investigated, and a close link to PMLNBs has been
identiﬁed. In unstressed cells HIPK2 levels are kept low by the ubiquitin
ligases Siah-1 (seven in absentia homolog-1) [62] andWSB-1 [63] and it
mainly resides in the nucleoplasm and in NBs whichmay correspond to
polycomb bodies [61]. Upon cellular stress, degradation of HIPK2 is
inhibited via ATM or the ATM- and Rad3-related kinase ATR [62] and a
fraction of HIPK2 is recruited to PML NBs, where it colocalizes with p53
and presumably phosphorylates p53 on Ser46 [38,39]. In addition,
HIPK2 binds the acetyl transferase CBP and enhances CBP-dependent
p53 acetylation at Lys382 [38], which contributes to full activation of
p53. HIPK2 can only efﬁciently phosphorylate p53 in the presence of
PML [64], and also the PMLNB component Sp100 seems to be important
for this function [65], indicating that PMLNBs could indeed be the site of
Ser46 phosphorylation. HIPK2-mediated phosphorylation of p53 occurs
after various kinds of DNA damage [38,39,66,67] and thus represents a
central mediator in the apoptosis-regulating properties of PML NBs.
Interestingly, earlier work revealed that oncogenic Ras-induced cellular
senescence also involves CBP-mediated acetylation of p53 at Lys382
[14]. It is currently unclear whether HIPK2 is also involved in this
process.
UV irradiation also induces the accumulation of TIP60 at PML NBs
[68]. TIP60 belongs to theMYST family of acetyl transferases and is able
to acetylate p53 at Lys120, and this acetylation was also shown to
facilitate p53-dependent apoptosis [69,70]. An additional layer of
complexity is added by the ﬁnding that the histone deacetylase SIRT1
can also localize to PML NBs and can reduce the acetylation of p53 at
Lys382 and thereby counteract apoptosis induction upon DNA damage
[71,72]. Intriguingly, the transcriptional repressor Daxx may also play a
role in p53-dependent apoptosis associatedwith PMLNBs [73]. A recent
report showed an interaction of Daxx with the HIPK2 interactor and -
activator axin [74], increasing the phosphorylation of p53 at Ser46.
Moreover, under steady-state conditions, Daxx can form a ternary
complex with MDM2 and the deubiquitinating enzyme HAUSP
(herpesvirus associated ubiquitin-speciﬁc protease), enhancing MDM2
Fig. 2. Control of p53 activity at PMLNBs. A hypotheticalmodel is shown. (a) In unstressed
cells, a complexof Daxx and the deubiquitinaseHAUSP stabilizes theMDM2/HDM2,which
polyubiquitinates p53 and leads to its proteasomal degradation. It is currently unclear
whether this takes place at PML NBs. HIPK2 mainly resides in non-PML NBs in absence of
genotoxic stress. (b) Upon cytotoxic stress, p53 is phosphorylated and the HAUSP-MDM2-
complex dissociates leading to MDM2 degradation and p53 stabilization. p53 is recruited
into PML NBs through interaction with PML-IV. These events uncouple p53 from MDM2-
dependent negative regulation. In response to severe genotoxic stress, HIPK2 is recruited
by PML-IV into PMLNBswere it forms a complexwith CBP and p53. HIPK2 phosphorylates
p53 at Ser46 and thereby regulates p53 acetylation at Lys382. This may affect p53's
interactions with cofactors and thus enhance its afﬁnity to target genes that drive the cell
into apoptosis or cellular senescence. This process is counteractedby the deacetylase SIRT1,
which deacetylates the p53 Lys382. The prolyl-isomerase Pin1 induces conformational
changes in p53 in response to p53 phosphorylation, potentiating p53 acetylation and
dissociation from MDM2. It is currently unclear whether this occurs at PML NBs or the
chromatin of the target promoters.
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hence to the degradation of MDM2,which in turn stabilizes p53 [75,76].
In parallel, HAUSP can directly stabilize p53 by deubiquitinating it, also
contributing to p53-mediated apoptosis [77].
Thus, several competing apoptosis-regulating mechanisms con-
verge at PML NBs (summarized in Fig. 2). Further research is required
to elucidate the crosstalk between activation and inactivation of p53,
as well as p53-dependent and -independent apoptosis regulation.
4. PML NBs and death-receptor signalling
PML NBs play also a role in apoptosis regulation via the extrinsic
apoptotic pathway (Fig. 3). For instance, the FLASH protein, also
termed CASP8AP2 (caspase-8 associated protein 2), which has beenoriginally implicated in caspase-8 activation at the level of the CD95
DISC [78], partially colocalizes with the PMLNB component Sp100 and
with PML itself [41]. FLASH was also found in Cajal bodies, where it
regulates histone gene expression and cell cycle progression [79,80].
Upon engagement of the death-receptor CD95/Fas in the type II cell
line HT1080, FLASH leaves NBs and migrates into the cytoplasm,
accumulates at mitochondria and interacts with and facilitates
cleavage of caspase-8, thereby enhancing cell death. Knockdown of
FLASH, in turn, renders the cells more resistant to extrinsic apoptosis
induction [41]. Interestingly, FLASH/CASP8AP2 appears to be a
prognostic marker in childhood acute lymphoblastic leukemia,
where lower levels of FLASH correlate with decreased sensitivity of
the leukemic cells to apoptosis induction and with less event-free
survival of the patients [81].
In leukemic blasts, it was found some years ago that TRAIL can be
upregulated by PML [82], but the factor that is targeted directly by
PML had not been identiﬁed. Interestingly, in a very recent study it
was shown that PML can enhance the activity of the transcription
factor NFAT (nuclear factor of activated T-cells), which induces the
transcription of the genes coding for FasL, TRAIL and TNFα, facilitating
death-receptor-mediated apoptosis [83].
The PML NB component Daxx has also been linked to death-
receptor-mediated apoptosis (recently reviewed in [84]). Daxx was
originally reported to promote apoptotic cell death by interacting with
the intracellular portion of CD95/Fas, either directly or via the death
domain protein FADD (Fas-associated death domain). Obviously, Daxx
also interacts with the pro-apoptotic kinase ASK1 (apoptosis signal-
regulating kinase1) and induces the CD95-JNK signalling axis to
engage the apoptosis machinery. In addition, Daxx is critical for JNK
activation via the TGF-β pathway and in response to oxidative stress or
UV irradiation. Moreover, Daxx can act as transcriptional repressor for
several transcription factors, for instance for the p65/RelA subunit of
the pro-survival factor NF-κB (nuclear factor-κB), thus preventing
expression of anti-apoptotic genes. Thus, it was suggested that Daxx
may indeedmodulate CD95-dependent apoptosis induction from PML
NBs rather than from the DISC. SUMO-1-conjugated Daxx can be
recruited by PML into PML NBs [33], a process which also requires a
SIM within Daxx [85]. NB-associated Daxx appears to be inactive with
respect to apoptosis induction [86], so under steady-state conditions,
PML would exert an anti-apoptotic function by blocking Daxx. Indeed,
in rheumatoid arthritis ﬁbroblasts, overexpression of SUMO-1
correlates with strong nuclear PML sumoylation, increased recruit-
ment of Daxx into PML NBs and resistance of the cells to CD95-
induced apoptosis [87]. Moreover, in PML NBs, Daxx partially
colocalizes with and is earmarked for degradation by Pin1, which
reduces death-receptor-mediated apoptosis via the Daxx-JNK (c-jun
N-terminal kinase)-pathway [56]. Conversely, HIPK2 was shown to
phosphorylate Daxx, which may release Daxx from PML NB [88].
Collectively, the effects of Daxx on different apoptosis pathways are
pleiotropic, and the relationship between these effects still remains to
be further investigated [84].
5. PML NBs and TGF-β receptor signalling
Less than 50% of the nuclear PML is actually sumoylated and
associated with NBs (e.g. [89]). The remaining half of the protein is
distributed throughout the nucleoplasm and was even shown to
shuttle to the cytoplasmic compartment. Some potentially tumouri-
genic mutations may act by sequestering nuclear PML, but also the
comparatively abundant normally occurring isoform PML-I probably
contains a functional nuclear export signal (NES) and is found in both
NBs and the cytoplasm [21]. Interestingly, there is evidence for a
function of cytoplasmic PML (cPML) in the transduction of TGF-β
(transforming growth factor-β) signals that cannot be fulﬁlled by
nuclear PML. Lin et al. could show that Pml−/− ﬁbroblasts are
refractory to TGF-β-induced apoptosis, and sensitivity of these cells
Fig. 3. Role of PML NBs in receptor-mediated apoptosis signalling. PML can inﬂuence the extrinsic apoptotic pathway at multiple sites. The FLASH protein, which is partially localized
in PML NBs where it interacts with Sp100, is released from NBs and the nucleus upon CD95 activation and is targeted to mitochondria. At mitochondria, FLASH facilitates caspase-8
processing and apoptosis induction via the mitochondrial pathway. The Daxx protein can transmit the CD95 death signal through activating the JNK pathway due to interactionwith
FADD at the CD95 DISC, and it may also participate in TGF-β-mediated JNK activation. Daxx also resides in PML NBs, where it may regulate TGF-β-dependent apoptosis by repress
pro-survival signalling (not shown). Daxxmay be released from PML NB after HIPK2-mediated phosphorylation. Moreover, p53 phosphorylated at Ser46 and acetylated at Lys382 can
activate genes coding for components of death-receptor pathways, such as CD95 receptor and its ligand, thus coupling the intrinsic and the extrinsic death pathway.
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of cPML, which is a predominantly cytoplasmic isoform that lacks the
sequence encoded by exons 4 to 6 [90]. Mechanistically, they showed
an interaction of cPML with both Smad2 (SMA and mothers against
decapentaplegic 2) and SARA (Smad anchor for receptor activation),
leading to a recruitment of these proteins to the early endosome
compartment. Another study presented evidence for an inhibitory
mechanism where TGIF (TG-interacting factor) forms a ternaryFig. 4. Role of PML NBs in p53- and death-receptor-independent apoptosis, and the con
independent manner when phosphorylated by Chk2 on Ser117 upon IR. Moreover, complexe
the THAP protein can also trigger apoptosis, whichmay occurmainly via themitochondrial pa
it can recruit active, phosphorylated-Akt kinase into NBs, where it is dephosphorylated by th
p65 into NBs and thereby prevent its binding to anti-apoptotic targets gene promoters.complex with c-jun and PML, sequestering cytoplasmic PML in the
nucleus and blocking its function in TGF-β signalling [91].
The multifunctional Daxx protein has also been implicated in
TGF-β signalling [92]. In this context, Daxx was found to interact
with the cytoplasmic domain of the type II TGF-β receptor and to be
critical for activation of the JNK pathway. How could PML NB-
associated Daxx be released from and targeted to the cytoplasm
where it is supposed to act in TGF-β signalling? A possible mediatortrol of survival signalling. PML can induce apoptosis in a Daxx- and death-receptor-
s of the pro-apoptotic protein PAR-4, the Dlk/ZIPK protein kinase, Daxx and presumably
thway. In addition, pro-survival signalling pathways are negatively regulated by PML, as
e phosphatase PP2A. Furthermore, PML can sequester the transactivating NF-κB subunit
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phosphorylate Daxx and to release Daxx from PML NBs when
exogenously expressed [88]. HIPK2 also appears to cooperate with
Daxx in TGF-β-dependent activation of JNK, which also leads to
apoptosis in a p53-independent manner [88]. This aspect of HIPK2
function was shown to be blocked by sumoylation of HIPK2, which
did not interfere with p53 phosphorylation at Ser46 [88]. However, it
is currently unclear whether HIPK2 controls Daxx localization under
physiological conditions.
6. PML NBs and other apoptosis pathways
A novel pathway that leads to PML-facilitated apoptosis indepen-
dently of p53 may involve the action of a complex of the death-
activated protein-like kinase DLK/ZIPK, Daxx [93], the nuclear pro-
apoptotic protein THAP1 and the prostate apoptosis-response factor
PAR-4 which antagonizes NF-κB [94]. These factors seem to interact at
PML NBs [95], but the mechanism by which this promotes apoptosis
remains to be clariﬁed, although it seems to involve the mitochondrial
pathway [96]. PML may also induce apoptosis in another p53-
independent manner that depends on its phosphorylation on Ser117,
which is mediated by Chk2 in response to ionizing-irradiation [97].
This work by Yang et al. revealed that a phosphorylation-mimetic PML
Ser117Glu mutant could induce apoptosis in p53-deﬁcient cells,
whereas Ser117Ala failed to do so. However, the pathway that is
affected by Ser117 phosphorylation affects neither death-receptor-
mediated apoptosis nor abundance and localization of Daxx and
therefore still remains to be identiﬁed. The current knowledge about
the alternative pathways by which PML can regulate apoptosis is
depicted in Fig. 4.
7. PML NBs and cell survival signalling
PML NBs can also regulate survival signalling. For instance, the
sensitivity of U2OS cells towards TNFα-induced apoptosis is enhanced
by the ability of PML to interact with and thereby block theFig. 5. Crosstalk between different nuclear bodies in apoptosis regulation. PML NBs and othe
For instance, the nucleolus shares ﬁbrillarin and NUPP140 with Cajal bodies. FLASH not exclu
PML NBs. HIPK2 NBs in unstressed cells may, in part, correspond to polycomb bodies. In res
sequester the p53 ubiquitin ligase MDM2/HDM2 to the nucleolus, which plays a critical ro
releasing p19Arf in response to cytotoxic stress, which then leads to the inhibition of MDM2 f
the activation of anti-apoptotic target genes.transcriptional activity of the NF-κB subunit RelA/p65 [32]. Further-
more, a recent study by Trotman et al. showed that PML mediates the
recruitment of phosphorylated Akt into NBs, where the phosphoryla-
tion mark is removed by the phosphatase PP2A [98]. This inhibits its
ability to phosphorylate FOXO (Forkhead box) transcription factors,
which increases their ability to activate pro-apoptotic target genes
such as Bim and TRAIL. Moreover, another study suggests that PML-IV
can repress the expression of the anti-apoptotic protein survivin on the
transcriptional level [99], thereby removing survivin from caspase-9
and facilitating apoptosome formation. It was shown that PML
represses the Survivin promoter independently of p53, but a direct
binding of PML to this region has not been demonstrated; therefore,
the PML effect may also occur via an intermediate factor associated
with PMLNBs. Thus, PMLnot onlyactively promotes apoptosis, but also
interferes with survival signalling pathways (Fig. 4).
8. Crosstalk of PML NBs with other NBs in apoptosis regulation
Several lines of evidence indicate crosstalk between PML NBs and
other nuclear domains (summarized in Fig. 5). PML NBs, similar to
other nuclear domains such as Cajal bodies or nucleoli, are dynamic
structures that constantly exchange their components with the
surrounding nucleoplasm and other NBs [10,100,101]. Some proteins
such as HIPK2, Sp100, FLASH or HDM2 have been found in other
nuclear domains, such as Cajal bodies (FLASH) [79,80] or the nucleolus
(HDM2) [102], or in as yet not fully characterized domains (HIPK2)
[38]. Moreover, PML NBs are often found in close proximity to Cajal
bodies (e.g. [80]), which may be due to an interaction between the
PML NB-associated protein PIASy and the constitutive Cajal body
component coilin [103]. Cajal bodies also seem to fragment into
smaller bodies upon UV irradiation, quite similarly to PML NBs [104].
Cajal bodies, in turn, share several proteins such as ﬁbrillarin with
nucleoli, and are often associated with nucleoli [105], which suggest
functional interplay and crosstalk with these domains.
Remarkably, nucleoli, which are established sensors for cell stress,
are the nuclear domains that share the most proteins with PML NBs,r subnuclear structures share various components and contribute to cell fate decisions.
sively resides in PML NBs, but also in Cajal bodies, which are often found juxtaposed to
ponse to DNA damage, HIPK2 is then partially recruited to PML NBs. PML was shown to
le as a stress sensor. The nucleolus can directly regulate p53-dependent apoptosis by
unction. Also, the NF-κB subunit p65 can be sequestered in the nucleolus, thus inhibiting
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cellular stress [106]. Indeed, it was shown that certain PML isoforms,
namely PML-I and PML-IV, can even form “nucleolar caps” upon
cellular stress [107], and that PML is able to sequester MDM2 to the
nucleolus in a manner dependent on ATR [102], thereby stabilizing
p53. Moreover, a recent study [108] suggests that the RelA subunit of
the pro-survival factor NF-κB can also be sequestered in the nucleus
after cytotoxic stress, which also increases apoptosis in affected cells,
although in this case, in contrast to the study by Wu et al. [32], PML
involvement has not been demonstrated. The nucleolar sequestration
of p65/RelA can also be induced by Cdk4 (cyclin-dependent kinase 4)
inhibition, either by p38 or by CDK4 inhibitors [109,110]. Moreover,
the tumour suppressor p19ARF (alternate reading frame) is localized
in the nucleolus in unstressed cells, in a complex with the
phosphoprotein nucleophosmin [111], and is released upon cytotoxic
stress [112], engaging the p53-dependent apoptotic pathway by
binding to MDM2. Interestingly, ARF mediates the sumoylation of
MDM2 [113], which it was also reported to sequester in the nucleolus
[114]. Very recent work suggests that localization of ARF in the
nucleolus is indeed mediated by nucleophosmin, but is not required
for the p53-activating function of ARF [115], supporting the hypothesis
that nucleolar sequestration of ARF rather promotes cell survival. The
nucleolus may modulate apoptosis in PML- and p53-independent
ways, for instance bystress-dependent release of nucleophosmin,
which then acts as a Bax chaperone that recruits Bax to mitochondria
to facilitate apoptosis [116], or by facilitating recruitment and
degradation of the recently identiﬁed survivin splice form survivin-
deltaEx3, which paradoxically seems to be required for its anti-
apoptotic function [117].
In summary, the nucleolus – beside PML NBs – is emerging as a
second subnuclear compartment with complex functions in apoptosis
regulation, exhibiting extensive crosstalk with PML NBs. Other nuclear
structures, such as the HIPK2 NBs, Cajal bodies and FLASH- and Sp100-
containing bodies, were also shown to exchange protein with PML
NBs, but a direct role of these compartments in apoptosis induction
has not been demonstrated yet.
9. PML and cancer
Apoptosis and cellular senescence are crucial mechanisms to
prevent cellular transformation and malignant cell growth of
damaged cells. Consistently, PML activity has been linked to tumour
suppression. In many cancer types, PML protein is reduced or almost
completely lost by post-transcriptional mechanisms [118,119], and
that loss is associated with tumour progression in prostate and breast
cancer. Most recently, it has also been shown that PML can repress
carcinogenesis by repressing the hypoxia-induced factor HIF1α (and
thereby tumour angiogenesis) by inhibitingmTOR [120]. Furthermore,
some human tumour virus-encoded proteins such as human
Papilloma virus (HPV) 18 E6 protein and the Hepatitis C virus (HCV)
core protein may contribute to the development of cervix or
hepatocellular carcinoma, respectively, by targeting PML functions at
PML NBs [121,122].
However, the classical example for the function of PML as a
suppressor of malignant cell growth is acute promyelocytic leukemia
(APL) (for a recent review, see [123]). The promyelocytes of more than
90% of patients that suffer from this disease express of a protein
chimera of PML fused to the retinoic receptor alpha (PML-RARα) that
is produced as a result of a reciprocal translocation between
chromosomes 15 and 17 [123]. The PML-RARα oncoprotein always
contains the RBCC domain of PML and can still interact with the
remaining wildtype PML in APL cells. However, PML-RARα does not
localize to NBs, but instead delocalizes PML into a microspeckled
pattern, blocking the activity of the wildtype PML expressed from the
intact allele in a dominant-negative manner [124,125]. Furthermore,
Gurrieri et al. identiﬁed mutations of the PML gene in two cases of APLwhich were particularly aggressive [119], indicating that loss of PML
function really is an important player in the pathogenicity of APL.
The APL cells have been shown to be resistant to some apoptotic
stimuli. For instance, TNFα-, but not CD95-mediated apoptosis is
strongly reduced in APL cells [126]. Moreover, overexpression of PML-
RARα in myeloid precursor cells was shown to inhibit their
differentiation and to prevent starvation-induced apoptosis [127].
Treatment of APL cells with retinoic acid (RA) has been shown to
revert the dominant-negative phenotype of PML-RARα by degrading
the chimeric protein, through caspase-mediated cleavage of PML-
RARα [128] or via the proteasomal pathway [129], re-establishing
functional PML NBs, although not directly inducing apoptosis, but
rather differentiation of the APL cells. In contrast, arsenic trioxide
(ATO), another potent therapeutic that is used to treat myeloid
leukemias, induces programmed cell death in APL cells [130]. ATO can
induce phosphorylation of PML by ERK2 (extracellular signal-
regulated kinase 2) in non-APL cells; interestingly, PML-RARα is also
phosphorylated by ERK2, but this does not result in SUMO modiﬁca-
tion of the hybrid protein [130]. However, ATO activates ATR kinase,
which then phosphorylates Chk2-T68 in a Chk1- and ATR-indepen-
dent manner. This results in PML-dependent autophosphorylation of
Chk2 which in turn triggers the p53-dependent apoptotic pathway
[131]. Moreover, ATO induces the degradation of PML-RARα, thus
enabling the wild type PML to relocalize to NBs, in which Chk2 is
autophosphorylated and fully activated, constituting a positive feed-
back loop enhancing apoptosis in the treated cells [132]. ATO also
reduces the levels of the anti-apoptotic protein Bcl-2 at the mRNA
level [133] and upregulates the death-receptor ligand TRAIL, which
was shown to induce apoptosis in APL cells in a paracrine manner
[134]. Remarkably, ATO not only leads to the degradation of RML-
RARα, but also that of wild type PML [135], which requires
sumoylation of PML at lysine 160 [136]. Two independent studies
now show that this degradation is mediated by RNF4/SNURF, the ﬁrst
known SUMO-chain speciﬁc E3 ubiquitin ligase [137,138]. This
suggests that PML NBs may be degradation centres for PML and
other PML-associated proteins such as Daxx, which are recruited to
PML NBs via SUMO binding. To date, it is entirely unclear under which
circumstances this mechanism has an impact on apoptosis regulation
by PML, since ATO-treated cells die by p53 dependent- and
independent apoptotic pathways, but RNF4-dependent degradation
also seems to occur under steady-state conditions [137], thus likely
preventing apoptosis and cellular senescence in unstressed cells by
keeping PML levels below a “dangerous” threshold.
10. Conclusions
It is now well established that PML NBs integrate cytotoxic stress
signals and are critical mediators of p53 dependent and -independent
apoptosis. Although some of the mechanisms by which NB-associated
PML can enhance apoptosis appear to be fairly well analysed, such as
the facilitation of the phosphorylation and acetylation of p53 upon
DNA damage induction, many questions await further investigation.
For instance, the relationship between different PML splice forms and
their potential differential regulation is far from clear. Along the same
lines, it has been shown that these splice forms do not localize to NBs
to the same extent, and kinetic analyses show that many PML isoforms
are exchanged within minutes between a given nuclear body and the
surrounding nucleoplasm, and can also be recruited to speciﬁc target
promoters or even to cytoplasmic structures, so that it will be a tough
task to really separate body-associated from nucleo- or cytoplasmic
functions of PML protein(s). The analysis of speciﬁc PML isoformsmay
also reveal novel interactions that may point to other regulatory
functions of PML NBs. Also, the often observed juxtaposition of PML-
and other NBs may be a hint that PML may inﬂuence or monitor more
intranuclear processes as previously anticipated by talking to other
NBs and vice versa. Moreover, some known interactions of PML with
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underlying mechanisms are unclear and require further investigation.
Finally, it will be highly interesting to clarify whether the RING-
domain protein PML itself inﬂuences cell fate decisions by acting as
either a ubiquitin ligase or a SUMO ligase, which was suggested by
experiments in yeast [18]. In addition, it remains to be studied
whether PML can recruit other sumoylated proteins to be regulated by
RNF4 or mechanistically-related ligases. This will allow important
insight into the mechanisms by which PML regulates the activity of its
interaction partners. Answers to these questions will help to draw a
more detailed picture about the role of PML NBs in cell fate regulation
and tumour suppression. This may allow us to forge novel molecular
weapons for the ﬁght against cancer.
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